Institut Pasteur

Institute of Microbiology of the Ascr, V.v.i.

Institute of Physiology of the Ascr, V.v.i.

Centre National De La Recherche Scientifique

Biotechnologicky Ustav Av Cr, V.v.i.

Peter Sebo

Claude Leclerc

Daniel Ladant

Radim Osicka

Agnes Ullmann

Catherine Fayolle

Marek Basler

Adriana Osickova

Jiri Masin

Jan Krusek

Fotini Betsou

Nicole Guiso

Cécile Bauche

Jirina Loucka

Mohammed El-Azami El-Idrissi

Nicole Gutso

Milan Kuchar

Hana Petrokova

Petr Maly

Lucie Vankova

The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. The mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.

Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

A polypeptide comprises a mutatedCyaA (SEQ ID NO:1),CyaA (SEQ ID NO:7),CyaA (SEQ ID NO:8), orCyaA (SEQ ID NO:9), or a fragment thereof lacking all or part of the N-terminal catalytic domain of the CyaA, or a polypeptide having at least 95% sequence identity with SEQ ID NOS: 1, 7, 8, or 9. The glutamic acid residue at position 570 of SEQ ID NO: 1, 7, 8 or at position 569 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. The lysine residue at position 860 of SEQ ID NO: 1, 7, 8 or at position 859 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. The polypeptide retains the binding activity of native CyaA to CD11b expressing cell, and has a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.

The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.

The invention relates to modifiedadenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection againstinfection. The invention also relates to specific fragments ofadenylate cyclase comprising the CD11b/CD18 interaction domain and their use, especially for targeting a molecule of interest to CD11b expressing cells.

[object Object]

Purified nucleic acids comprising a nucleotide sequence encoding an immunogenic polypeptide of adenyl cyclase-haemolysin (AC-Hly), which induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of, andwhen the nucleic acid or polypeptide is administered to a human or animal host. The nucleic acids are useful, for example, to induce a protective immune response in a host against infection by a bacteria selected from the group consisting of, and

Nucleic acids encoding protective epitopes of adenyl cyclase-haemolysin (AC-Hly)

The subject of the invention is amino acid sequences of the AC-Hly fromand/or, carrying epitopes capable of inducing a protective immune response against infection by. The subject of the invention is antibodies, especially monoclonal antibodies, directed against these epitopes.

Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections

The subject of the invention is amino acid sequences of the AC-Hly from,and/or,carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the invention is antibodies, especially monoclonal antibodies, directed against these epitopes.

This invention relates to a recombinant plasmid comprising the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella adenylate cyclase in a transformed host cell. This invention also relates to a recombinat DNA molecule comprising the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. This invention further relates to recombinant Bordetella adenylate cyclase comprising a heterologous epitope at a permissive site as well as methods of inducing a specific B cell, helper T cell, and CTL cell immune response.

Recombinant mutants for inducing specific immune responses

A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.

Growing community of inventors

Prague, Czechia

Peter Sebo